4.6 Review

Primary Neuroendocrine Tumor of the Breast: Current Understanding and Future Perspectives

Journal

FRONTIERS IN ONCOLOGY
Volume 12, Issue -, Pages -

Publisher

FRONTIERS MEDIA SA
DOI: 10.3389/fonc.2022.848485

Keywords

primary neuroendocrine carcinoma of the breast; neuroendocrine neoplasia; clinicopathologic characteristics; diagnosis; treatment; prognosis; literature review

Categories

Funding

  1. Liaoning Province Key Laboratory Project of Breast Cancer Research [2016-26-1]
  2. Shenyang Breast Cancer Clinical Medical Research Center [2020-48-3-1]
  3. Dalian University of Technology [LD202022]
  4. Beijing Medical Award Foundation [YXJL-2020-0941-0752]
  5. Wu Jieping Medical Foundation [320.6750.2020-12-21, 320.6750.2020-6-30, 320.6750.18541]

Ask authors/readers for more resources

Primary neuroendocrine carcinoma of the breast (NECB) is a rare and poorly differentiated subtype of breast cancer. The accurate diagnosis and treatment of NECB remain challenging due to its low incidence and lack of standardized guidelines. This review provides an overview of the latest research on the clinicopathologic characteristics, diagnosis, treatment, and prognosis of NECB, as well as new perspectives on its molecular features.
Primary neuroendocrine carcinoma of the breast (NECB) is characterized with heterogeneity, rarity, and poor differentiation, which is probably an underestimated subtype of breast cancer, including small cell NECs and large cell NECs. The diagnostic criteria for NECB have been constantly updated as the disease changes and the understanding increases. According to the latest WHO Classification, primary neuroendocrine neoplasm (NEN) of the breast consists of well-differentiated neuroendocrine tumors (NET), extremely aggressive neuroendocrine carcinomas (NEC) as well as invasive breast cancers of no special type (IBCs-NST) with neuroendocrine differentiation. The accurate diagnosis of NECB remains a challenge for its low incidence, which needs multi-disciplinary methods. For the rarity of the disease, there is a lack of large samples and prospective clinical research. For these invasive tumors, there are no standardized therapeutic guidelines or norms, and the treatment often refers to nonspecific breast cancer. In addition, the prognosis of such patients remains unknown. In 2003, the World Health Organization (WHO) listed NECB as an independent entity for the first time, while few features of NECB were clarified. In this review, it presents the WHO Classification, clinicopathologic characteristics, diagnosis, treatment, and prognosis of these patients. In addition, it summarizes the latest studies on molecular features of NECB, aiming to provide new therapeutic perspectives for the disease.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available